logo
"Razor blade throat": The "Nimbus" COVID variant sparks concern of summer surge

"Razor blade throat": The "Nimbus" COVID variant sparks concern of summer surge

Yahooa day ago

Post-pandemic amnesia is a natural reaction, and it's common for misremembering to occur after a pandemic or collective traumatic event occurs. Yet the reality is that SARS-CoV-2, the virus causing COVID-19, is still finding ways to infect people by evolving new mutations, and a new variant has raised concern among virologists that continue to track the virus.
Last month, the World Health Organization labeled the COVID variant NB.1.8.1 a 'variant under monitoring' because it has been surging across Asia and made up 10.7% of global sequences reported as of mid-May. Now, the variant has been detected in the United States, Europe and Canada as well, concerning virus trackers who — for the first time since the Pirola variant began circulating in August 2023 — bestowed upon it a nickname: Nimbus.
Nimbus has recombined genetic material from other strains three times. Although the process of recombination is a natural process of viruses trying to evolve to survive among the population, recombination events are concerning because each time a virus does so, it has the potential to evolve into something that is more infectious or causes more severe disease.
One of these mutations in Nimbus allows it to evade the immunity we have built against the virus from prior infections, so transmissibility might be slightly higher, said Dr. Rajendram Rajnarayanan, of the New York Institute of Technology campus in Jonesboro, Arkansas.
A recent preprint study, not yet peer-reviewed, found that the way this variant binds to cells could make it infect them more efficiently than earlier strains and that it could be easier for this strain to be passed along to someone else. However, there has not been any evidence yet to suggest that Nimbus is linked to more severe illness.
'We haven't seen a big surge in emergency departments due to COVID-related conditions and respiratory things in this term yet,' Rajnarayanan told Salon in a video call. 'We have to wait and watch.'
Recently, many people have been reporting a symptom called 'razor blade throat,' but it's unclear if this is a symptom of COVID or one of the many other viruses circulating. Overall, it is difficult to attribute certain symptoms to variants when there are more than a dozen circulating at a time and testing remains relatively low compared to earlier stages of the pandemic, said Dr. T. Ryan Gregory, an evolutionary and genome biologist at the University of Guelph in Canada.
'That said, we learned from Omicron that high transmissibility can cause as much damage as high per infection virulence, and at this point it is not just acute severity that is of concern, but longer-term impacts of repeated infection,' Gregory told Salon in an email. Such impacts include conditions like "long COVID," in which the symptoms of COVID last for months or years, often disabling patients.Nevertheless, current data shows that most COVID infections in the U.S. are currently caused by the LP.8.1 variant, which descends from Pirola. Both of these strains are technically still in the WHO's Greek letter 'Omicron' family, which now contains thousands of offspring. If there's one thing viruses are good at, it's mutating into new forms that can evade our immunity, whether that's from vaccines or past infections.
In 2023, the WHO decided to only name variants with this system if they were considered a 'variant of concern' and stated that certain action steps should be taken by countries if a variant fell under this classification. However, the agency has not labeled any variants like this since Omicron.
Some argue that some variants have been different enough to warrant a new name, and that not naming variants makes it more difficult to distinguish between the complex alphabet soup of variants that are circulating at any given time.
For example, Pirola, which included the BA.2.86 variant along with its descendants, was about as genetically different from the original Omicron strain as Omicron was from the original 'wild strain' virus from Wuhan, China.
Nevertheless, in the past two years, 'it's largely been the Pirola show,' Gregory said. Current vaccines have been designed to protect against this strain.
So far, Nimbus is not very common in the U.S., but it has been identified in California and has enough mutations in its spike protein that it has a potential to cause waves of illness in other regions — which is in part why it was designated a name. At-home tests should still work to detect this variant, but PCR tests that doctors can order are more accurate. Masking also helps prevent the spread of the virus.
Every year following the start of the COVID pandemic, cases have surged in the summer. Last year's summer surge hit around August and was so intense that vaccines were approved slightly early. Although this year's summer wave hasn't yet started, experts predict we will likely experience another wave this summer. As it stands, variant trackers expect either Nimbus or another variant called XFG to be the dominant strain this time around. Although XFG currently makes up a greater proportion of cases in North America than NB.1.8.1, the latter has been detected in New York and California.
'NB.1.8.1 is a strong candidate for the summer surge,' Rajnarayanan said. 'Yet what we know from previous instances is that it doesn't have to be a single variant that pushes up [to prominence] and sometimes it can be a group of variants … that pick up mutations from each other and recombine.'
The good news is that Nimbus is still similar enough to the Pirola variants that the available vaccines were designed to target. That means they should still be effective, Gregory said. However, concerns have been raised that vaccine access may be limited this fall due to the Food and Drug Administration announcing it would require drugmakers to conduct a new set of clinical trials before approving new vaccines for use. Last month, the FDA also said it will only recommend COVID vaccines for adults 65 and older and those at risk for severe illness. Critics have said this will only make the vaccines less likely to be covered by insurance and less available overall.
On Monday, secretary of the Department of Health and Human Services Robert F. Kennedy announced he was firing the expert panel that advises the Centers for Disease Control responsible for making recommendations on vaccines, further complicating matters.
Paired with updated guidelines from the CDC that drop recommendations for healthy pregnant women and kids to routinely get vaccinated, these changes from the federal government could have a chilling effect that leads fewer people to get vaccinated.
'I'm concerned about accessibility,' Rajnarayanan said, adding that it's not clear if vaccines will be available to people without insurance that aren't included in federal recommendations. 'These kinds of things are still murky and I really want to see clearer guidelines.'
While many people may seem to have forgotten about COVID, people are still routinely hospitalized and killed by the virus. Additionally, each COVID nfection carries a risk of going on to develop long Covid, which continues to debilitate millions of people. As we witnessed when COVID was a full-blown pandemic, emerging viruses can be especially damaging for people with existing conditions like diabetes, obesity and heart disease.
It's important to protect against things like long COVID not only for the well-being of people today but also for our susceptibility to future viruses, Rajnarayanan said.
'In different parts of the world, I've seen funding for continuous surveillance gone down, and not just for surveillance, which is important, but also studying the disease itself,' Rajnarayanan said. 'This is not just about protecting [people] today but also protecting them from any other variant in the future.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025
Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025

Yahoo

timean hour ago

  • Yahoo

Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025

– Revumenib was generally well-tolerated in combination with venetoclax/azacitidine in older, newly diagnosed mNPM1 and KMT2Ar AML patients – – Promising clinical activity and deep responses observed with 67% (29/43) CR rate, 88% (38/43) ORR, and 100% (37/37) MRD negativity among responders – – Enrollment underway in pivotal Ph 3 EVOLVE-2 trial evaluating revumenib with ven/aza in newly diagnosed mNPM1 AML patients unfit for intensive chemotherapy – NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that data from the BEAT AML trial of revumenib in combination with venetoclax and azacitidine (ven/aza) in newly diagnosed mutant NPM1 (mNPM1) and KMT2A-rearranged (KMT2Ar) acute myeloid leukemia (AML) patients were published in the Journal of Clinical Oncology and simultaneously presented in an oral session at the 30th European Hematology Association (EHA) Annual Congress Meeting being held June 12-15, 2025, in Milan, Italy and virtually. 'The data observed in BEAT AML underscore the potential for revumenib with ven/aza to improve outcomes for newly diagnosed mNPM1 or KMT2Ar AML patients who are not eligible for intensive chemotherapy, a population that continues to face poor long-term outcomes despite recent advances,' said Nick Botwood, M.B.B.S., Head of Research & Development and Chief Medical Officer at Syndax. 'These data, along with the results from other trials of revumenib in different settings, highlight revumenib's potential to become a cornerstone therapy for all menin-dependent acute leukemias across the treatment continuum.' 'These data support the ability to combine revumenib with ven/aza in the frontline setting and the clinical activity observed highlights the potential for the triplet to provide high rates of complete remission and MRD-negativity, two treatment goals associated with improved clinical outcomes,' said Joshua F. Zeidner, M.D., Chief, Leukemia Research at the University of North Carolina, Lineberger Comprehensive Cancer Center and Principal Investigator in the BEAT AML trial. 'Overall, the data we observed in BEAT AML are very encouraging and suggest that the ongoing EVOLVE-2 pivotal frontline trial evaluating the triplet in unfit mNPM1 AML patients could deliver practice-changing results.' Summary of Results from BEAT AML Phase 1 Trial The publication and EHA presentation report updated results from the Phase 1b BEAT AML trial evaluating the safety and clinical activity of revumenib in combination with venetoclax/azacitidine in newly diagnosed older adults (≥60 years) with mNPM1 or KMT2Ar AML. The trial is being conducted as part of The Leukemia & Lymphoma Society's Beat AML® Master Clinical Trial (NCT03013998). As of September 2024, 43 patients were enrolled and treated in BEAT AML across two dose levels of revumenib (113 mg q12 or 163 mg q12h with strong CYP3A4 inhibitor azoles) in combination with venetoclax and azacitidine. Overall, 79% (34/43) of patients had mNPM1 AML and 21% (9/43) had KMT2Ar AML. The median age was 70 years (range: 60-92) and 40% were ≥75 years. Revumenib was generally well tolerated at both dose levels in combination with venetoclax and azacitidine without a maximal tolerated dose identified. The most common overall non-hematologic treatment-emergent adverse events (TEAEs) of any grade were nausea (60%), constipation (53%), QTc prolongation (44%), hypokalemia (44%), and vomiting (42%). Overall Grade ≥3 non-hematologic AEs were rare and similar between both dose levels. In the intent-to-treat population, the observed rate of complete remission (CR) was 67% (29/43), composite complete remission (CRc) was 81% (35/43), and the overall response rate (ORR) was 88% (38/43). Among 37 patients with measurable residual disease (MRD) response assessment, 100% were MRD negative by centralized flow cytometry testing (sensitivity of 0.02%). The median duration of CRc was 12.0 months (95% CI: 7.8-not reached). 23% (10/43) of patients had proceeded to hematopoietic stem cell transplantation (HSCT) as of the February 2025 data cut off. In an early analysis of survival from this single-arm trial (median follow-up of 6.9 months), the median overall survival (OS) observed was 15.5 months (95% CI: 9.5-19.5). Subset analysis showed a CRc rate of 77% and an observed median OS of 15.5 months in mNPM1 patients with intermediate risk by ELN 2024 (n=17), and a CRc rate of 89% and observed median OS of 18.0 months in KMT2Ar patients (n=9). In contrast, historical data from newly diagnosed mNPM1 patients with intermediate risk treated with venetoclax and azacitidine show a CRc of 57% and median OS of 9.9 months.1 In newly diagnosed KMT2Ar AML patients treated with venetoclax and hypomethylating agent therapy, a CRc rate of 43% and median OS of 2.5 months was observed in a retrospective analysis.2 About Revuforj® (revumenib) Revuforj (revumenib) is an oral, first-in-class, selective menin inhibitor that is FDA approved for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients one year and older. Revumenib is in development for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1). Positive pivotal data from the AUGMENT-101 trial in this population with revumenib as a monotherapy were recently published and the Company completed the submission of a supplemental NDA for revumenib in R/R mNPM1 AML in April 2025. Additionally, multiple trials of revumenib in combination with standard-of-care agents in mNPM1 AML or KMT2A-rearranged acute leukemia are ongoing or planned across the treatment landscape, including in newly diagnosed patients. Revumenib was previously granted Orphan Drug Designation for the treatment of AML, ALL and acute leukemias of ambiguous lineage (ALAL) by the U.S. FDA and for the treatment of AML by the European Commission. The U.S. FDA also granted Fast Track designation to revumenib for the treatment of adult and pediatric patients with R/R acute leukemias harboring a KMT2A rearrangement or NPM1 mutation and Breakthrough Therapy Designation for the treatment of adult and pediatric patients with R/R acute leukemia harboring a KMT2A rearrangement. IMPORTANT SAFETY INFORMATION WARNING: DIFFERENTIATION SYNDROME Differentiation syndrome, which can be fatal, has occurred with Revuforj. Signs and symptoms may include fever, dyspnea, hypoxia, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, hypotension, and renal dysfunction. If differentiation syndrome is suspected, immediately initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution. WARNINGS AND PRECAUTIONS Differentiation syndrome: Revuforj can cause fatal or life-threatening differentiation syndrome (DS). Symptoms of DS, including those seen in patients treated with Revuforj, include fever, dyspnea, hypoxia, peripheral edema, pleuropericardial effusion, acute renal failure, and/or hypotension. In clinical trials, DS occurred in 39 (29%) of 135 patients treated with Revuforj. DS was Grade 3 or 4 in 13% of patients and fatal in one. The median time to onset was 10 days (range 3-41 days). Some patients experienced more than 1 DS event. Treatment interruption was required for 7% of patients, and treatment was withdrawn for 1%. Reduce the white blood cell count to less than 25 Gi/L prior to starting Revuforj. If DS is suspected, immediately initiate treatment with systemic corticosteroids (e.g., dexamethasone 10-mg IV every 12 hours in adults or dexamethasone 0.25-mg/kg/dose IV every 12 hours in pediatric patients weighing less than 40 kg) for a minimum of 3 days and until resolution of signs and symptoms. Institute supportive measures and hemodynamic monitoring until improvement. Interrupt Revuforj if severe signs and/or symptoms persist for more than 48 hours after initiation of systemic corticosteroids, or earlier if life-threatening symptoms occur such as pulmonary symptoms requiring ventilator support. Restart steroids promptly if DS recurs after tapering corticosteroids. QTc interval prolongation: In the clinical trials, QTc interval prolongation was reported as an adverse reaction in 39 (29%) of 135 patients treated with Revuforj. QTc interval prolongation was Grade 3 in 12% of patients. The heart-rate corrected QT interval (using Fridericia's method) (QTcF) was greater than 500 msec in 8%, and the increase from baseline QTcF was greater than 60 msec in 18%. Revuforj dose reduction was required for 5% of patients due to QTc interval prolongation. QTc prolongation occurred in 16% of the 31 patients less than 17 years old, 33% of the 88 patients 17 years to less than 65 years old, and in 50% of the 16 patients 65 years or older. Correct electrolyte abnormalities, including hypokalemia and hypomagnesemia, prior to treatment with Revuforj. Perform an electrocardiogram (ECG) prior to initiation of Revuforj, and do not initiate Revuforj in patients with QTcF >450 msec. Perform an ECG at least once weekly for the first 4 weeks and at least monthly thereafter. In patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval, more frequent ECG monitoring may be necessary. Concomitant use with drugs known to prolong the QTc interval may increase the risk of QTc interval prolongation. Interrupt Revuforj if QTcF increases >480 msec and <500 msec, and restart Revuforj at the same dose twice daily after the QTcF interval returns to ≤480 msec Interrupt Revuforj if QTcF increases >500 msec or by >60 msec from baseline, and restart Revuforj twice daily at the lower-dose level after the QTcF interval returns to ≤480 msec Permanently discontinue Revuforj in patients with ventricular arrhythmias and in those who develop QTc interval prolongation with signs or symptoms of life-threatening arrhythmia. Embryo-fetal toxicity: Revuforj can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment with Revuforj and for 4 months after the last dose of Revuforj. ADVERSE REACTIONS Fatal adverse reactions occurred in 4 (3%) patients who received Revuforj, including 2 with differentiation syndrome, 1 with hemorrhage, and 1 with sudden death. Serious adverse reactions were reported in 99 (73%) patients. The most frequent serious adverse reactions (≥5%) were infection (24%), febrile neutropenia (19%), bacterial infection (17%), differentiation syndrome (12%), hemorrhage (9%), and thrombosis (5%). The most common adverse reactions (≥20%) including laboratory abnormalities, were hemorrhage (53%), nausea (51%), phosphate increased (50%), musculoskeletal pain (42%), infection (41%), aspartate aminotransferase increased (37%), febrile neutropenia (35%), alanine aminotransferase increased (33%), parathyroid hormone intact increased (33%), bacterial infection (31%), diarrhea (30%), differentiation syndrome (29%), electrocardiogram QT prolonged (29%), phosphate decreased (25%), triglycerides increased (25%), potassium decreased (24%), decreased appetite (24%), constipation (23%), edema (23%), viral infection (23%), fatigue (22%), and alkaline phosphatase increased (21%). DRUG INTERACTIONS Drug interactions can occur when Revuforj is concomitantly used with: Strong CYP3A4 inhibitors: reduce Revuforj dose Strong or moderate CYP3A4 inducers: avoid concomitant use with Revuforj QTc-prolonging drugs: avoid concomitant use with Revuforj. If concomitant use is unavoidable, obtain ECGs when initiating, during concomitant use, and as clinically indicated. Withhold Revuforj if the QTc interval is >480 msec. Restart Revuforj after the QTc interval returns to ≤480 msec. SPECIFIC POPULATIONS Lactation: advise lactating women not to breastfeed during treatment with Revuforj and for 1 week after the last dose. Pregnancy and testing: Revuforj can cause fetal harm when administered to a pregnant woman. Verify pregnancy status in females of reproductive potential within 7 days prior to initiating Revuforj. Pediatric: monitor bone growth and development in pediatric patients. Geriatric: compared to younger patients, the incidences of QTc prolongation and edema were higher in patients 65 years and older. Infertility: based on findings in animals, Revuforj may impair fertility. The effects on fertility were reversible. To report SUSPECTED ADVERSE REACTIONS, contact Syndax Pharmaceuticals at 1-888-539-3REV or FDA at 1-800-FDA-1088 or Please see Full Prescribing Information, including BOXED WARNING. About Syndax Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit or follow the Company on X and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "could," "estimate," "expects," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative or plural of those terms, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Syndax's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, clinical development and scope of clinical trials, the reporting of clinical data for Syndax's product candidates, the acceptance of Syndax and its partners' products in the marketplace, sales, marketing, manufacturing and distribution requirements, and the potential use of its product candidates to treat various cancer indications and fibrotic diseases. Many factors may cause differences between current expectations and actual results, including: unexpected safety or efficacy data observed during preclinical or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; changes to Revuforj's or Niktimvo's commercial availability; changes in expected or existing competition; changes in the regulatory environment; failure of Syndax's collaborators to support or advance collaborations or product candidates; and unexpected litigation or other disputes. Other factors that may cause Syndax's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Syndax's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Syndax assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. All other trademarks are the property of their respective owners. References Döhner H, et al. Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine. Blood 2024; 144 (21): 2211– 222. Gangat N, et al. Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent. Am J Hematol. 2025;100(2):260-271. Syndax Contact Sharon KlahreSyndax Pharmaceuticals, Tel 781.684.9827 SNDX-GError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Home Medical Equipment Market is expected to grow at a steady CAGR of 4.5% through 2034
Home Medical Equipment Market is expected to grow at a steady CAGR of 4.5% through 2034

Yahoo

timean hour ago

  • Yahoo

Home Medical Equipment Market is expected to grow at a steady CAGR of 4.5% through 2034

Home Medical Equipment MarkeT Outlook, Trends and Forecast to 2034 Luton, Bedfordshire, United Kingdom, June 12, 2025 (GLOBE NEWSWIRE) -- Market Overview The global home medical equipment market is witnessing a transformative shift driven by evolving healthcare delivery models, technological integration, and rising patient preference for at-home care. Valued at approximately USD 45 billion in 2024, the market is projected to grow at a Compound Annual Growth Rate (CAGR) of 4.5%, reaching USD 69 billion by 2034. This steady growth is primarily supported by an aging global population, the increasing prevalence of chronic illnesses, and the subsequent need for cost-effective, home-based health management solutions. Patients and caregivers are increasingly leaning towards home care due to its convenience, affordability, and ability to reduce hospital readmissions. Download PDF Brochure: Key Growth Drivers A significant driver of market expansion is the growing burden of chronic diseases such as diabetes, cardiovascular disorders, and respiratory conditions. These require ongoing management, often best conducted in the comfort of a patient's home. Additionally, the global demographic shift towards an older population has intensified the demand for home-based care, especially for patients with mobility limitations or long-term conditions. The advancement and adoption of telehealth, Internet of Things (IoT)-enabled devices, and wearable healthcare technology further contribute to this growth. These innovations have made it easier for patients to track their health metrics remotely and for healthcare professionals to monitor progress without physical visits. Enhanced connectivity and patient engagement tools are also driving better clinical outcomes, thus fueling adoption. Market Restraints and Challenges Despite promising growth prospects, the home medical equipment market faces notable hurdles. Regulatory variability across regions poses challenges for device approvals and commercialization. The lack of harmonized standards often leads to delays in product launches and increases compliance costs. Moreover, disparate reimbursement policies across countries complicate the adoption of home medical devices, especially in low-to-middle-income economies where public health coverage is limited. Supply chain disruptions, worsened by global events such as the COVID-19 pandemic and geopolitical tensions, have led to raw material shortages and increased production costs. Moreover, pricing pressures and competition from low-cost manufacturers further strain profit margins, making it difficult for companies to balance affordability and innovation. Segmentation Analysis By Product Type The market is segmented into monitoring and therapeutic devices, mobility assist devices, home respiratory equipment, sleep apnea devices, wound care, IV equipment, and other categories. Monitoring and therapeutic devices dominate the segment, accounting for roughly 30% of the market share. These include glucose monitors, blood pressure monitors, and other devices critical for chronic disease management. Their adoption is fueled by technological integration, especially telehealth compatibility. Mobility assist devices, including wheelchairs and walkers, contribute approximately 20% of the total share. Their demand is closely tied to the aging population and innovations such as lightweight materials and ergonomic designs. Home respiratory equipment, which includes oxygen concentrators and nebulizers, holds an 18% share. The spike in respiratory ailments, including long-term effects of COVID-19, has significantly driven growth in this segment. By End User The homecare settings segment leads the market with around 40% of the demand, driven by growing patient preference for personalized care and economic savings compared to institutional care. Hospitals, although traditionally dominant, now account for 25%, often engaging in partnerships with homecare providers to manage post-discharge care. Rehabilitation centers and long-term care facilities represent about 15%, supported by integrated care models that combine therapeutic and mobility support at home. By Distribution Channel Direct sales channels, where companies sell products directly to consumers or care facilities, account for nearly 30% of the market. This approach offers customized solutions and stronger customer relationships. Online sales, contributing to 28%, are growing rapidly due to consumer convenience and the rising popularity of e-commerce. Meanwhile, retail pharmacies and medical equipment stores together represent about 20%, supported by their accessibility and integration with health services. By Demographics The geriatric population makes up 60% of the market, reflecting their higher demand for home medical equipment due to age-related conditions. Adults, particularly those managing chronic conditions at home, contribute 25%, while the pediatric segment comprises 15%, driven by parental preferences for home-based treatment solutions. Browse full Report - Market Segmentation Product Type: Monitoring and Therapeutic Devices Mobility Assist Devices Home Respiratory Equipment Sleep Apnea Devices Wound Care Equipment Home IV Equipment Other Home Healthcare Equipment End-User: Hospitals Homecare Settings Rehabilitation Centers Long-term Care Facilities Assisted Living Facilities Distribution Channel: Direct Sales Online Sales Retail Pharmacies Medical Equipment Stores Demographics: Age Group (Pediatrics, Adults, Geriatrics) Gender (Male, Female) Socioeconomic Status (Low, Medium, High-income groups) Regional Insights North America leads the global market, contributing approximately 40% of total revenue in 2024. The region benefits from robust healthcare infrastructure, favorable reimbursement policies, and a high prevalence of chronic conditions. Technological adoption is also significantly high, with telemedicine and IoT devices becoming standard in many care settings. North America is projected to maintain a healthy CAGR of 5.5% through 2034. Europe holds around 25% of the global share, led by countries such as Germany and France. The region is characterized by a growing elderly population, supportive homecare policies, and well-established healthcare systems. The forecast CAGR for Europe is 4.8%, driven by demand for remote care solutions and wearable devices. Asia-Pacific, accounting for 20% of market share in 2024, is expected to grow at the fastest CAGR of 7.2%. Key contributors include China, India, and Japan, where rising disposable incomes, healthcare awareness, and investments in healthcare infrastructure are accelerating adoption. However, regulatory complexities and regional disparities remain challenges. Latin America and the Middle East are emerging regions, each showing potential with projected CAGRs of 6.4% and 6.1%, respectively. Improvements in healthcare access, economic reforms, and increased awareness of homecare benefits are aiding growth, though infrastructural and regulatory barriers persist. Key Market Trends and Opportunities An increasing focus on preventive healthcare is shaping demand for home diagnostics and early detection devices. This shift is accompanied by growing interest in wearables, AI-enabled analytics, and remote patient monitoring systems, offering a promising frontier for device manufacturers. New business models, including equipment-as-a-service and subscription-based offerings, are gaining popularity. These provide affordability and flexibility to users while ensuring stable revenue streams for providers. Moreover, partnerships between device manufacturers and digital health platforms are becoming a norm, resulting in integrated care solutions that improve patient adherence and satisfaction. Emerging areas of opportunity include mental health support tools and chronic disease management platforms, both of which require consistent monitoring and therapy that can be effectively managed at home. As healthcare transitions toward a patient-centric model, home medical equipment companies have a unique opportunity to redefine care delivery. Buy Now: Recent Market Developments Key Competitors Philips Healthcare Invacare Corporation Medtronic ResMed Baxter International Inc. Johnson & Johnson Fresenius Medical Care AG & Co. KGaA Hill-Rom Holdings, Inc. Drive DeVilbiss Healthcare Arjo AB GE Healthcare Omron Healthcare SunMed Amedisys Inc. althera Health1. Philips Healthcare Month & Year: October 2023 Type of Development: Product Launch Detailed Analysis: In October 2023, Philips Healthcare launched an innovative range of portable home ventilators aimed at improving respiratory care for patients with chronic obstructive pulmonary disease (COPD). This launch is significant as it responds to an increasing global demand for at-home healthcare solutions, especially post-pandemic, where many patients prefer or are required to manage their health from home. The portable nature of these ventilators facilitates easy transport and increased accessibility, appealing to both consumers and healthcare providers seeking to enhance patient care. As healthcare systems globally pivot towards value-based care models, products like Philips' new ventilators may help drive a competitive edge by offering enhanced patient-centric solutions, thereby potentially increasing market shares among key competitors. This strategic move reflects a trend towards integrating advanced technology in home medical equipment, likely setting new standards for functionality and user experience. 2. Invacare Corporation Month & Year: September 2023 Type of Development: Acquisition Detailed Analysis: Invacare Corporation announced its acquisition of a leading telehealth platform in September 2023, marking a pivotal shift towards digital healthcare integration within home medical equipment. This acquisition aligns with emerging trends that emphasize remote patient monitoring and telehealth services, which have surged in demand since the pandemic. The significance of this move lies in Invacare's commitment to providing comprehensive home care solutions that not only offer medical equipment but also integrate vital telehealth technologies. By enhancing their product offerings to include remote monitoring capabilities, Invacare positions itself to capture a growing segment of the market that values digital health tools. Moreover, this acquisition may prompt competitive shifts, as it encourages other players to innovate and expand their offerings in line with technological advancements, further transforming the home healthcare sector. 3. Medtronic Month & Year: August 2023 Type of Development: Regulatory Approval Detailed Analysis: In August 2023, Medtronic obtained regulatory approval for its latest remote monitoring system, designed for chronic disease management in home settings. This system enables healthcare providers to monitor patient health metrics in real-time, facilitating proactive care interventions. The significance of this approval cannot be overstated, considering the increasing emphasis on reducing hospital readmissions and improving care efficiency. Medtronic's system stands to reshape care pathways by allowing timely decision-making based on comprehensive patient data. With the home healthcare market projected to grow substantially, this advancement could drive competitive advantage, compelling other companies to pursue similar regulatory pathways to enhance their offerings. As the technology gains traction, it may also highlight a shift toward integrated care solutions that leverage data analytics and remote technologies, indicating an evolution in home care's operational model. 4. ResMed Month & Year: July 2023 Type of Development: Partnership Detailed Analysis: July 2023 saw ResMed enter into a strategic partnership with a leading digital health company to enhance sleep apnea treatment through data-driven solutions. The partnership aims to integrate wearable technology to monitor sleep patterns effectively and personalize therapy for patients using ResMed devices. This collaboration is significant as it reflects a growing trend towards integrating artificial intelligence and machine learning into patient care. By leveraging technology, ResMed not only improves treatment efficacy but also elevates patient engagement, making adherence to treatment protocols more intuitive. The collaboration could lead to increased market share and customer loyalty for ResMed, setting a precedent for other players to engage in similar innovative partnerships. Those companies that fail to adopt such integrative approaches may find themselves at a competitive disadvantage as the market increasingly values connected healthcare solutions. 5. Baxter International Inc. Month & Year: June 2023 Type of Development: Expansion Detailed Analysis: In June 2023, Baxter International Inc. announced its expansion into the Asian market with the opening of a new manufacturing facility dedicated to home intravenous therapy products. This move reflects Baxter's strategic focus on growing international revenues amidst increasing local demand for home care solutions. By tapping into the burgeoning Asian economy, which is witnessing a rapid shift towards home healthcare due to its cost-effectiveness and patient preference, Baxter is poised to significantly bolster its market presence. This expansion also signifies a competitive shift, as it may encourage other global players to target emerging markets aggressively. The trend towards localized production not only facilitates faster response times to market demands but also positions companies like Baxter to capitalize on regional healthcare initiatives aimed at reducing hospital overcrowding, thereby influencing the overall landscape of home healthcare products. This report is also available in the following languages : Japanese (在宅医療機器市場), Korean (가정용 의료 장비 시장), Chinese (家庭医疗设备市场), French (Marché des équipements médicaux à domicile), German (Markt für medizinische Geräte für den Heimgebrauch), and Italian (Mercato delle apparecchiature mediche domestiche), etc. Request Sample Pages: More Research Finding – Medical Assistive Technology Market The global medical assistive technology market is valued at approximately $45 billion in 2024, with a projected growth to around $81 billion by 2034. This represents a robust Compound Annual Growth Rate (CAGR) of 6.2% from 2025 to 2034. Orthopedic Rehabilitation Aids Market The global orthopedic rehabilitation aids market is poised to reach an estimated value of approximately $10 billion in 2024, driven by an aging population and increasing incidence of musculoskeletal disorders. During the forecast period from 2025 to 2034, the market is projected to expand at a Compound Annual Growth Rate (CAGR) of 6.8%, potentially reaching around $20 billion by 2034. Rehabilitation Medical Device Market The global rehabilitation medical device market is valued at approximately $19.2 billion in 2024, with projections indicating significant growth to reach around $31.5 billion by 2034. This reflects a robust Compound Annual Growth Rate (CAGR) of around 5.1% during the forecast period from 2025 to 2034. Medical Rehabilitation Equipment Market The global medical rehabilitation equipment market is valued at approximately $14 billion in 2024, with expectations to reach around $25 billion by 2034, indicating a robust growth trajectory. This represents a Compound Annual Growth Rate (CAGR) of about 6.4% from 2025 to 2034. Amyotrophic Lateral Sclerosis Device Market The global market for amyotrophic lateral sclerosis (ALS) devices is valued at approximately $2.1 billion in 2024. This market is anticipated to reach around $3.6 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of 5.3% during the forecast period from 2025 to 2034. Aid for The Elderly and Disabled Market The global market for aid for the elderly and disabled is projected to reach approximately $95 billion in 2024, with expectations to expand significantly over the next decade. By 2034, the market value is forecasted to soar to around $150 billion, reflecting a robust Compound Annual Growth Rate (CAGR) of approximately 4.7% during the period from 2025 to 2034. Assistive Devices For The Elderly and Disabled Market The global market for assistive devices for the elderly and disabled is valued at approximately $35 billion, with a robust projected growth trajectory. By 2034, this market is anticipated to reach $70 billion, reflecting a Compound Annual Growth Rate (CAGR) of about 7.3%. Stroke Assistive Devices Market The stroke assistive devices market is valued at approximately $2.5 billion in 2024, driven by the increasing prevalence of strokes and a growing geriatric population. This segment is expected to reach around $4.5 billion by 2034, reflecting a robust investment in healthcare infrastructure and advanced rehabilitation solutions. The projected Compound Annual Growth Rate (CAGR) during the forecast period from 2025 to 2034 is estimated at 6.1%. U.S. Physical Therapy Equipment Market The U.S. physical therapy equipment market is valued at approximately $3.2 billion in 2024, with expectations to reach around $5.2 billion by 2034, reflecting a Compound Annual Growth Rate (CAGR) of about 5.0% during the forecast period from 2025 to 2034. Pulsed Light Medical Equipment Market The global pulsed light medical equipment market is poised for significant growth, with a current valuation of approximately $540 million in 2024. Projecting forward, this market is expected to reach around $1.2 billion by 2034, reflecting robust demand driven by advancements in medical technology and increasing adoption of non-invasive treatment options. The market is anticipated to grow at a Compound Annual Growth Rate (CAGR) of about 8% during the forecast period from 2025 to 2034. Xenon Flash Lamp Market The global xenon flash lamp market is valued at approximately $450 million in 2024, with projections indicating a robust growth trajectory, reaching approximately $675 million by 2034. This represents a compound annual growth rate (CAGR) of around 4.5% over the forecast period from 2025 to 2034. Polarizing Beam Splitters PBS Market The global market for polarizing beam splitters (PBS) is valued at approximately $1.2 billion in 2024, with an anticipated expansion to $2.5 billion by 2034. This growth trajectory suggests a robust Compound Annual Growth Rate (CAGR) of around 8.1% during the forecast period from 2025 to 2034. Special Equipment Manufacturing Market The global special equipment manufacturing market is projected to reach approximately USD 250 billion in 2024. This sector encompasses a diverse array of industries, including construction, mining, and specialized machinery. The market is expected to exhibit robust growth, reaching an estimated value of USD 425 billion by 2034, reflecting a Compound Annual Growth Rate (CAGR) of 5.3% from 2025 to 2034. Plasma Cleaners Market The global plasma cleaners market is valued at approximately $450 million, with projections estimating a market value of around $1.1 billion by 2034. This growth trajectory reflects a Compound Annual Growth Rate (CAGR) of about 9% over the forecast period from 2025 to 2034. Strain Wave Gearing Devices Market The global strain wave gearing devices market is estimated to reach a valuation of approximately USD 550 million in 2024, with a robust projected growth trajectory anticipating a market value of around USD 1.1 billion by 2034. This reflects a notable Compound Annual Growth Rate (CAGR) of approximately 7.2% over the forecast period from 2025 to 2034. Galvanometer Scanners Market The global galvanometer scanners market is expected to reach a value of approximately $250 million in 2024, driven by rising demand across industries such as medical, defense, and manufacturing for precise laser applications and automation. Projections for the market suggest a robust growth trajectory, with a forecasted value of about $450 million by 2034. Pet Medical Equipment Market The global pet medical equipment market is poised for significant growth, with an estimated market value of approximately $1.5 billion in 2024. Forecasts indicate a robust expansion, anticipating the market will reach around $2.9 billion by 2034, driven by increasing pet ownership and rising expenditure on pet healthcare. 5-axis CNC Machine Tool Market The global 5-axis CNC machine tool market is valued at approximately $3.5 billion in 2024, with forecasts indicating significant growth, projecting a market value of around $5.8 billion by 2034. This trajectory suggests a robust Compound Annual Growth Rate (CAGR) of about 5.3% during the forecast period from 2025 to 2034. Coaxial Isolators Market The global coaxial isolators market is valued at approximately $1.2 billion in 2024, with projections indicating it will reach around $1.9 billion by 2034. This growth signals a robust Compound Annual Growth Rate (CAGR) of 4.8% during the forecast period from 2025 to 2034. CONTACT: Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Kentucky families must renew Medicaid for first time since pandemic. Here's what to know
Kentucky families must renew Medicaid for first time since pandemic. Here's what to know

Yahoo

timean hour ago

  • Yahoo

Kentucky families must renew Medicaid for first time since pandemic. Here's what to know

Starting in July, thousands of families across Kentucky must again renew their Medicaid enrollment— a process one local health provider warns could leave some without necessary insurance coverage. During the COVID-19 pandemic, Kentucky halted annual Medicaid renewals, allowing participants to automatically be reenrolled. In 2023, the state ended that policy, requiring Medicaid recipients to go back to submitting enrollment paperwork every year — except for those in the Kentucky Children's Health Insurance Program (KCHIP). KCHIP is a free health insurance program for families with an income at or under 218% of the federal poverty level — or up to $70,000 per year for a family of four. Children under 19, pregnant mothers and mothers within one year of postpartum are eligible to receive KCHIP coverage. When recertification resumed in 2023, the state introduced several flexibilities to ensure vulnerable populations could remain covered, including extending automatic renewal for KCHIP participants. The goal was 'simplify the renewal process, reduce inappropriate terminations and allow the state to manage the increased workload,' according to a document from the Kentucky Department of Medicaid Services. Now, that flexibility is ending, meaning thousands of Kentucky families will start receiving notices to update and recertify their Medicaid eligibility. Here's what to know. Families will get a letter when it's time to recertify and should watch for notices by mail, phone and email. There are also several ways to check Medicaid eligibility and recertify if needed. Visit Call 855.4kynect (855.459.6328) to speak with a caseworker. Visit your local Department for Community Based Services office. Contact a state kynector for assistance through Once enrolled, coverage lasts for 12 months. Even if changes make families ineligible for the program, children retain coverage for the year. Families can miss notifications to reenroll for a lot of reasons, said Bart Irwin, CEO of Family Health Centers, a nonprofit primary care provider with locations across Louisville. Maybe they've changed addresses, incorrectly filled out paperwork or missed deadlines — but that doesn't mean they are not financially eligible for Medicaid or KCHIP. "There's a connection that if parents or caregivers lose Medicaid, it's highly likely a child will lose Medicaid too," Irwin said. "I don't quite understand the connection, but one [reason] I would think is that if the parents miss the opportunity or don't respond correctly to the state's inquiry on their own behalf, it's likely they're not going to on their child's behalf, too." If someone does not respond to a renewal by the deadline, they will be unenrolled from coverage. KCHIP participants and families can call 855-459-6328 as soon as they learn they are unenrolled for lack of response. If they are determined eligible within 90 days of termination, coverage may be rolled back to the day of termination. Irwin said recertification for the KCHIP program could artificially deflate Medicaid rolls, similar to when the state stopped automatic enrollment for adults on Medicaid in 2023. Between April, when recertification restarted, and December 2023, Jefferson County saw more than 28,500 drop off the program's rolls, according to data from the Cabinet of Health and Family Services. Children make up a substantial portion of Medicaid recipients in Jefferson County, with over 108,000 kids receiving coverage. A third of Family Health Centers' Medicaid patients are children under 19. "It would be the same process as going through our kynectors and helping them redo certification, we know they're eligible, right?" Irwin said. "It's going to be the bureaucratic process that's going to harm the kids. It's missing the letter, or not putting the right information in, or forgetting some information, that's what's going to knock kids off." Reach reporter Keely Doll at kdoll@ This article originally appeared on Louisville Courier Journal: Kentucky families must again renew Medicaid. Here's how to recertify

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store